突变型p53在弥漫性大B细胞淋巴瘤中作用的研究进展

doi:10.19739/j.cnki.issn1001-9510.2020.05.019

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (933 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Diffuse large B-cell lymphoma is one of the heterogeneous hematological malignancy accounting for approximately a third of non-Hodgkin lymphomas, with versatile clinical, morphological and molecular characteristics. P53 is an important tumor suppressor gene, which inhibits the occurrence and development of tumors by inducing cell cycle arrest, DNA repair and apoptosis, and regulating multiple signal transduction pathways. The cell cycle disorder and the inactivation of signal transduction pathway caused by p53 mutation are factors in the occurrence and progression of many malignant tumors. This article reviews the role of mutationtype p53 (mutp53) in diffuse large B-cell lymphoma and its possible mechanisms.

Key words： diffuse large B-cell lymphoma p53 gene mutation review

Received: 28 March 2020

PACS:

R733.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Hongyan
	QU Guimei

Cite this article:

LI Hongyan,QU Guimei. Advanced progress of mutp53 in diffuse large B-cell lymphoma[J]. 滨州医学院学报, 2020, 43(5): 395-398.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2020.05.019 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2020/V43/I5/395

[1] SWERDLOW S H,CAMPO E,PILERI S A,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood,2016,127(20): 2375-2390.
[2] SEHN L H.Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma[J].Hematology Am Soc Hematol Educ Program,2012,2012: 402-409.
[3] XU-MONETTE Z Y,MEDEIROS L J,LI Y,et al.Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies[J].Blood,2012,119(16): 3668-3683.
[4] WHIBLEY C,PHAROAH P D,HOLLSTEIN M.p53 polymorphisms: cancer implications[J].Nat Rev Cancer,2009,9(2): 95-107.
[5] ZLAMALIKOVA L,MOULIS M,RAVCUKOVA B,et al.Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas[J].Oncol Rep,2017,38(4): 2535-2542.
[6] ZENZ T,KREUZ M,FUGE M,et al.TP53 mutation and survival in aggressive B cell lymphoma[J].Int J Cancer,2017,141(7): 1381-1388.
[7] SCHIEFER A I,KORNAUTH C,SIMONITSCH-KLUPP I,et al.Impact of single or combined genomic alterations of tp53,myc,and bcl2 on survival of patients with diffuse large b-cell lymphomas: a retrospective cohort study[J].Medicine (Baltimore),2015,94(52): e2388.
[8] EDAGAWA M,KAWAUCHI J,HIRATA M,et al.Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib[J].J Biol Chem,2014,289(31): 21544-21561.
[9] BUROKER N E.Regulatory SNPs and transcriptional factor binding sites in ADRBK1,AKT3,ATF3,DIO2,TBXA2R and VEGFA[J].Transcription,2014,5(4): e964559.
[10] PARK H Y,LEE S B,YOO H Y,et al.Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma[J].Oncotarget,2016,7(52): 86433-86445.
[11] LU T X,YOUNG K H,XU W,et al.TP53 dysfunction in diffuse large B-cell lymphoma[J].Crit Rev Oncol Hematol,2016,97: 47-55.
[12] ZHOU G,WANG J,ZHAO M,et al.Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation[J].Mol Cell,2014,54(6): 960-974.
[13] TONIGOLD M,ROSSMANN A,MEINOLD M,et al.A cisplatinresistant head and neck cancer cell line with cytoplasmic p53mut exhibits ATPbinding cassette transporter upregulation and high glutathione levels[J].J Cancer Res Clin Oncol,2014,140(4): 1689-1704.
[14] HOUDE V P,DONZELLI S,SACCONI A,et al.AMPK beta1 reduces tumor progression and improves survival in p53 null mice[J].Mol Oncol,2017,11(9): 1143-1155.
[15] WORMANN S M,SONG L,AI J,et al.Loss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth,stroma modification,and gemcitabine resistance in mice and is associated with patient survival[J].Gastroenterology,2016,151(1): 180-193.
[16] KOTLER E,SHANI O,GOLDFELD G,et al.A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation[J].Mol Cell,2018,71(1): 178-190.
[17] WANG X J,MEDEIROS L J,BUESO-RAMOS C E,et al.P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement,expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma[J].Mod Pathol,2017,30(2): 194-203.
[18] TAMIMI Y,AL-HARTHY S,AL-HADDABI I,et al.The p53 MutationDeletion Profile in a Small Cohort of the Omani Population with Diffuse Large B-Cell Lymphoma[J].Sultan Qaboos Univ Med J,2014,14(1): e50-58.
[19] LI Y,GORDON M W,XU-MONETTE Z Y,et al.Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program[J].Blood,2013,121(22): 4529-4540.
[20] LI L,XU-MONETTE Z Y,OK C Y,et al.Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma[J].Oncotarhet,2015,6(27): 23157-23180.
[21] GU L,GE Z,WANG Y,et al.Activating transcription factor 3 promotes intestinal epithelial cell apoptosis in Crohn′s disease[J].Pathol Res Pract,2018,214(6): 862-870.
[22] Y W,M Z,H X,et al.Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPKERK signaling pathway[J].Oncotarget,2017,8(42): 72182-72196.
[23] XIA Y,XU-MONETTE Z Y,TZANKOV A,et al.Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma[J].Leukemia,2017,31(3): 625-636.
[24] KAZANTSEVA M,HUNG N A,MEHTA S,et al.Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression[J].Sci Rep,2017,7(1): 1566.
[25] B K,S M,J S,et al.Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy[J].Proc Natl Acad Sci USA,2019,116(44): 22288-22293.